Procalcitonin
Payments companies reported to CMS as associated with Procalcitonin. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Procalcitonin, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Procalcitonin
These are the largest totals companies reported as associated with Procalcitonin. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| James Neuenschwander | Mount Vernon, OH | Emergency Medicine | $12,231.23 |
| Michael Mansour | Boston, MA | Internal Medicine | $11,595.53 |
| James Newton | Fayetteville, AR | Infectious Disease | $11,384.40 |
| Eric Gluck | Chicago, IL | Hospitalist | $10,702.43 |
| Anders Berg | Boston, MA | Clinical Pathology/Laboratory Medicine | $10,250.00 |
| Padmashree Woodham | Macon, GA | Maternal & Fetal Medicine | $9,779.63 |
| Subbian Karumanchi | Boston, MA | Nephrology (Internal Medicine) | $8,169.94 |
| Patrick Cullinan | San Antonio, TX | Critical Care Medicine (Internal Medicine) | $5,951.86 |
| Thomas File | Akron, OH | Infectious Disease | $5,865.45 |
| Hung Nguyen | Loma Linda, CA | Critical Care Medicine (Internal Medicine) | $4,500.00 |
Prescribed Procalcitonin?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.